Johnathon Liddicoat

Johnathon Liddicoat

Auto-generated profile, based on publicly available information

Johnathon Liddicoat

Centre for Law, Medicine, and Life Sciences (LML), Faculty of Law, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
DNDianne Nicol
Dianne Nicol
LELisa Eckstein
Lisa Eckstein
MMMichael Morrison
Michael Morrison
JSJacob S. Sherkow
Jacob S. Sherkow
MOMargaret Otlowski
Margaret Otlowski
RMRebekah E. McWhirter
Rebekah E. McWhirter
Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.

4 May 2016 in Journal of Law and the Biosciences
Verified
Journal Article
Open access
PDF file
DNDianne Nicol
Dianne Nicol
TBTania Bubela
Tania Bubela
DCDon Chalmers
Don Chalmers
JCJan Charbonneau
Jan Charbonneau
CCChristine Critchley
Christine Critchley
NZNik Zeps
Nik Zeps
As US President Barack Obama noted in his 2015 State of the Union address, precision medicine promises to deliver ‘the right treatments, at the right time, every time to the right person’ which ‘gives us one of the greatest opportunities for new medical breakthroughs that we have ever seen’. 1 These comments were a prelude to a $215 million funding commitment by the President to his Precision Medicine Initiative, the aim of which is to ‘pioneer a new model of patient-powered research that promises to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients’. 2 The objectives include an undertaking to modernize the current regulatory landscape.

11 September 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MAMateo Aboy
Mateo Aboy
JLJohnathon Liddicoat
Johnathon Liddicoat
KLKathleen Liddell
Kathleen Liddell
MJMatthew Jordan
Matthew Jordan
CCCristina Crespo
Cristina Crespo

8 November 2016 in Nature Biotechnology
Verified
Journal Article
Closed access
MAMateo Aboy
Mateo Aboy
KLKathleen Liddell
Kathleen Liddell
JLJohnathon Liddicoat
Johnathon Liddicoat
CCCristina Crespo
Cristina Crespo

31 August 2019 in Annual Review of Genomics and Human Genetics
Verified
Journal Article
Open access
DNDianne Nicol
Dianne Nicol
RDRochelle C. Dreyfuss
Rochelle C. Dreyfuss
EGE. Richard Gold
E. Richard Gold
WLWei Li
Wei Li
JLJohn Liddicoat
John Liddicoat
GOGeertrui Van Overwalle
Geertrui Van Overwalle
This review explores the recent divergence in international patent law relating to genes and associated subject matter. This divergence stems primarily from decisions of the highest courts in the United States and Australia on the eligibility of patent claims relating to the BRCA gene sequences. Patent offices, courts, and policy makers have struggled for many years to clearly articulate the bounds of patent claims on isolated and synthetic DNA and related products and processes, including methods for their use in genetic diagnostics. This review provides context to the current divergence by mapping key events in the gene patent journey from the early 1980s onward in five key jurisdictions: the United States, the member states of the European Patent Convention, Australia, Canada, and China. Early approaches to gene patenting had some commonalities across jurisdictions, which makes exploration of the recent divergence all the more interesting.There is insufficient empirical evidence to date to confidently predict the consequences of this recent divergence. However, it could potentially have a significant effect on local industry and on consumer access.

13 April 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MAMateo Aboy
Mateo Aboy
KLKathleen Liddell
Kathleen Liddell
MJMatthew Jordan
Matthew Jordan
CCCristina Crespo
Cristina Crespo
JLJohnathon Liddicoat
Johnathon Liddicoat